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6 mo of the study. Furthermore, six study patients 
treated with ursodeoxycholic acid failed therapy, indi- 
cating that not all PBC patients treated with ursode- 
oxycholic acid therapy respond. Of equal importance, no 
patient in either group was noted to have a complete 
clinical, biochemical and histological remission, which 
remains the gold standard by which we judge treatment 
efficacy. 
Thus, in summary, the results of this study evaluating 
ursodeoxycholic acid therapy in PBC suggest we may 
have yet another drug that is associated with hepatic 
biochemical improvements and that may have some 
modest effect on reducing pruritus. However, with 
regard to hepatic fibrosis, little or no effect was appar- 
ently seen. Furthermore, the study falls short in telling 
us whether a difference exists in response in subgroups 
of patients based on disease severity. Patients in the 
clinically most advanced stages of disease were excluded 
from this study, and the investigators failed to address 
whether patients with histologically early stage disease 
responded better than patients who had histologically 
advanced (fibrotic/cirrhotic) stage disease. It is im- 
portant to point out that preliminary studies from other 
centers (10) have suggested that those patients with 
histological stage 3-4 disease (fibrotic/cirrhotic) have 
little or no response to ursodeoxycholic acid therapy. 
Furthermore, studies (11) have suggested that the 
beneficial biochemical effect of ursodeoxycholic acid 
therapy may be only temporary and that after a certain 
period of time hepatic biochemistries again worsen and 
the disease appears to progress. Finally, other studies 
(12) have suggested no beneficial effect of ursodeoxy- 
cholic acid is seen in PBC patients after 1 yr of therapy. 
Clearly, a major advantage of ursodeoxycholic acid 
therapy is its low toxicity rate. However, its substantial 
cost will make it important to clearly establish the 
efficacy of this drug before widespread use in the 
treatment of PBC. Thus the major questions not 
answered by this study are the following: (a) Are the 
beneficial effects of ursodeoxycholic acid in PBC sus- 
tainable? (b) Will treatment with ursodeoxycholic acid 
prolong time to development of cirrhosis, prevent or 
prolong time to development of complications of portal 
hypertension and prolong survival time free of liver 
failure? It appears essential to continue to evaluate 
ursodeoxycholic acid therapy in long-term, controlled 
clinical trials to further address these very important 
questions concerning efficacy. 
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HEPATITIS A. NEW INFORMATION ON AN 
OLD VIRUS 
Rosenblum LS, Villarino ME, Nainan OV, Melish ME, 
Hadler SC, Pinsky PP, Jarvis WB, et al. Hepatitis A 
outbreak in a neonatal intensive care unit: risk factors 
for transmission and evidence of prolonged viral ex- 
cretion among preterm infants. J Infect Dis 1991;164: 
476-482. 
ABSTRACT 
An outbreak of hepatitis A virus (HAV) infection in a 
neonatal intensive care unit (NICU) provided the 
opportunity to examine the duration of HAV excretion 
in infants and the mechanisms by which HAV epi- 
demics are propagated in NICUs. The outbreak af- 
fected 13 NICU infants (20%), 22 NICU nurses (24%), 8 
other staff caring for NICU infants, and 4 household 
contacts; 2 seropositive infants (primary cases) re- 
ceived blood transfusions from a donor with HAV 
infection. Risk factors for infection among nurses were 
care for a primary infant-case (relative risk [RR], 3.2), 
drinking beverages in the unit (odds ratio [OR], m), 
and not wearing gloves when taping an intravenous 
line (OR, 13.7). Among infants, risk factors were care by 
a nurse who cared for a primary infant-case during the 
same shift (RR, 6.1). Serial stool samples from infant- 
cases were tested for HAV antigen (HAV-Ag) by enzyme 
immunoassay and HAV RNA by nucleic acid amplifi- 
cation using the polymerase chain reaction. Infant- 
cases excreted HAV-Ag (n = 2) and HAV RNA (n = 3) 
4-5 months after they were identified as being infected. 
Breaks in infection control procedures and possibly 
974 HEPATOLOGY Elsewhere HEPATOLOGY 
prolonged HAV shedding in infants propagated the 
epidemic in a critical care setting. 
COMMENTS 
Hepatitis A virus (HAV) has been a known important 
cause of viral hepatitis since the discovery of the viral 
antigen in feces in 1973 (1). Despite the strict attention 
paid to infection control in most neonatal intensive care 
units (NICUs) several large outbreaks of HAV infection 
have occurred in these settings over the past decade 
(2-5). Although HAV infection is usually spread by way 
of a fecal-oral route, the index case in this report and 
others (3, 4) was not an infected health care worker or 
parent but an infant who received a blood transfusion 
contaminated with HAV. Transmission of HAV by blood 
transfusion is uncommon, but donors in the prodromal 
phase of hepatitis A have been shown to transmit the 
infection by way of blood transfusion. HAV viremia is 
estimated to last 2 to 3 wk at most and occurs during the 
late incubation period of the virus. During this incu- 
bation period the donor’s AST and ALT are often 
normal, and thus contaminated blood is not identified by 
AST or ALT screening (5 ) .  As expected from previous 
studies, no evidence was seen in this report for direct 
maternal-fetal transmission of HAV infection (6). 
Breaks in infection control procedures used in NICUs 
had obviously occurred because 27% of the susceptible 
full-time nursing personnel, 16% of the respiratory 
technicians and 32% of the infants became infected. 
Furthermore, two household contacts of infected nurses 
and two family members of infected infants also had 
HAV infection develop. The novel and important finding 
of this study was that the authors were able to identify 
risk factors for the subsequent infection of health care 
personnel and infants. Not surprisingly, those nurses 
who cared for one of the two primary infant cases were 
3.2 times more likely to be infected than nurses who had 
not cared for these infants during the period of active 
infection. Other risk factors for HAV infection included 
working the night shift, easily contaminating the hands 
(e.g., not wearing gloves when taping intravenous lines 
or endotracheal tubes and having long fingernails) and 
engaging in behaviors that resulted in direct hand-to- 
mouth contact (e.g., smoking and drinking beverages in 
the unit). Surprisingly, the practice of not wearing 
gloves during diaper changes was not associated with a 
significant increased risk of infection; which had been 
the case with other enteric infections in day-care 
centers. The study does not exclude the possibility that 
blood-borne exposure may have played a role in the 
spread of the infection within the neonatal intensive 
care unit because the procedures that placed nurses in 
contact with blood and other bodily secretions also 
placed them at a high risk for infection, whereas diaper 
changing did not. The authors were able to confirm that 
hospital personnel did facilitate infection of other 
infants because care by a nurse who cared for a primary 
infant case was associated with a sixfold increased risk 
of infection among secondary infant cases. This report 
again emphasizes the need for strict adherence to 
infection control procedures for all health care per- 
sonnel. 
Impaired clearance of the organism from infected 
neonates was investigated by the authors as a possible 
reason for the large size of the outbreak. Adults infected 
with HAV are not infectious and cease to  excrete fecal 
HAV antigen within 3 wk after the onset of symptoms 
(7). Although HAV infection in children is much more 
likely to be asymptomatic than in adults, fecal excretion 
studies of HAV antigen have not been performed in 
children. One study showed that during the second week 
of illness children were more likely to  have detectable 
fecal viral antigen (46%) than adults (14%), suggesting 
that children do indeed harbor the virus for a longer 
period of time; however, this study was not extended for 
a greater length of time (8). In the present study, three 
infected infants were observed for longer than 2 mo, and 
continued fecal excretion of HAV antigen was seen for 1 
to 4 mo longer than expected. The authors correctly 
concluded that this prolonged excretion of the virus 
probably worsened the HAV outbreak. One might 
question whether the neonatal immune response was 
brisk enough to clear the virus promptly. Although the 
immune response in neonates and preterm infants is 
poor, all 11 infected neonates had anti-HAV IgM develop 
within 8 wk of exposure, which is similar to studies in 
adults. Although the development of anti-HAV anti- 
bodies is associated with HAV immunity in adults, the 
role of the cell-mediated immune response in clearing 
the initial infection remains to be explained (9). Future 
studies will no doubt be conducted on the role of the 
cell-mediated immune response to HAV infection not 
only in the clearance of the virus but also its possible 
effect on determining the severity of infection. 
As has been the case with other viral infections such 
as hepatitis B, more sensitive methods of viral detection 
have better defined the period of infectivity. The 
polymerase chain reaction (PCR) is currently the most 
sensitive assay for the detection of viral RNA or DNA. In 
this study the authors extracted fecal RNA and reverse 
transcribed the HAV RNA to form a complementary 
DNA strand that was subsequently amplified. PCR has 
been used in the past to amplify HAV RNA and sequence 
the produced complementary DNA to identify different 
HAV genotypes in different parts of the world (10). 
Consistent with the sensitivity of the technique, the 
authors were able to detect HAV RNA by PCR for 1 to 
2 mo longer than they were able to detect HAV antigen. 
Although it remains unclear whether the detection of 
HAV RNA in the absence of HAV antigen represents 
true infectious virus, one infant in the present study 
continued to excrete HAV RNA for 6 mo after the onset 
of infection without detectable HAV antigen in the stool. 
This infant was the probable source of HAV infection for 
a nurse at least 5 mo after the infant had been identified 
as being infected. At that time the infant’s stools were 
positive for HAV RNA, suggesting that HAV RNA 
detection by PCR represents true infectivity. Unfortu- 
nately, the authors were unable to amplify and sequence 
the HAV RNA in the nurse’s stools and compare it with 
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that of the infected infant to determine whether the 
infant was the true source of infection. This report does, 
however, raise several important clinical questions that 
can be answered with further studies using PCR 
technology. The questions include the following: (a) 
Because PCR is much more sensitive than any previous 
method for the detection of HAV, what is the actual 
length of time for HAV fecal shedding? (b) Does the 
detection of HAV RNA without antigen represent true 
infectivity? (c) Does prolonged shedding of infectious 
virus occur in neonates and older children? (d) Because 
the study suggests prolonged shedding in neonates, does 
this extend to other immunocompromised hosts as well? 
(e) Although only one HAV serotype exists, can PCR be 
used to identify HAV genotypes responsible for more 
severe or prolonged infections? PCR has proven to be an 
important tool for the detection of HBV DNA, for 
the identification of HCV RNA and now will un- 
doubtedly be used to further our understanding of 
hepatitis A as well. 
CHRIS J. DICKINSON, M.D. 
University of Michigan Medical School 
Ann Arbor, Michigan 481 09 
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